Formalizes 1-for-50 Reverse Stock Split, Details Timetable for Share Consolidation
ATHE sits 74% above its 52-week low of $2.66.
Summary
Alterity Therapeutics has formally notified of a 1-for-50 reverse stock split, consolidating its ordinary shares and options, with a record date set for June 4, 2026.
Key Events · Corporate Governance and Compliance · ATHE
-
1-for-50 Reverse Stock Split Confirmed
The company formally announced a 1-for-50 reverse stock split, consolidating every 50 existing shares into 1 new share. This follows the general meeting proposal announced on April 29, 2026.
-
Impacts All Securities
The consolidation applies to all ordinary fully paid shares (ATH) and numerous outstanding options, adjusting their quantities and exercise prices proportionally.
-
Timetable Established
Key dates include a security holder meeting on May 29, 2026, a record date of June 4, 2026, and trading in post-consolidation securities commencing on a deferred settlement basis on June 3, 2026.
Analysis · ATHE · Life Sciences
This filing formalizes the previously announced proposal for a highly aggressive 1-for-50 reverse stock split, which will significantly reduce the number of outstanding shares and increase the per-share price. While often undertaken to meet exchange listing requirements or attract institutional investors, such a substantial consolidation is typically viewed negatively by the market as it can signal underlying financial challenges or precede further dilutive capital raises. Investors should monitor the stock's performance post-split and any subsequent financing activities.
At the time of this filing, ATHE was trading at $4.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $77.4M. The 52-week trading range was $2.66 to $7.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.